Cost-effectiveness of systemic therapies for metastatic pancreatic cancer

PURPOSE: Gemcitabine and capecitabine (gem-cap), gemcitabine and erlotinib (gem-e), and folfirinox (5-fluorouracil–leucovorin–irinotecan–oxaliplatin) are new treatment options for metastatic pancreatic cancer, but they are also more expensive and potentially more toxic than gemcitabine alone (gem)....

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Tam, V.C., Ko, Y.J., Mittmann, N., Cheung, M.C., Kumar, K., Hassan, S., Chan, K.K.W.
Formato: Artigo
Idioma:Inglês
Publicado: Multimed Inc. 2013
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3615875/
https://ncbi.nlm.nih.gov/pubmed/23559890
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.20.1223
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares